EyePoint, Inc. 8-K

What Happened

• On July 30, 2026, EyePoint, Inc. (EYPT) filed an 8-K (Item 8.01) and issued a press release announcing that it has completed enrollment in the pivotal Phase 3 clinical trials evaluating DURAVYU™ for the treatment of diabetic macular edema (DME). The press release is attached as Exhibit 99.1 to the filing.

Key Details

• Date of filing/announcement: July 30, 2026.
• Program: DURAVYU™ (investigational treatment for DME).
• Milestone: Completion of enrollment in pivotal Phase 3 trials (no efficacy or timing of readouts disclosed in the 8-K).
• Filing signed by George O. Elston, Executive Vice President and Chief Financial Officer.

Why It Matters

• Completing enrollment is a major clinical development milestone: it means the company has recruited the full planned patient population for its pivotal trials, allowing the studies to proceed to follow-up, analysis and eventual reporting of results. For investors, this reduces a near-term operational risk related to recruitment and keeps the clinical program on track; the timing and outcome of future data releases will be the next material events to monitor. The 8-K does not provide trial results or a timeline for data readouts.